Versant Vantage II GP, L.P. has filed a report detailing significant ownership changes in Lycia Therapeutics, Inc. This filing, dated October 22, 2026, is crucial as it indicates the venture capital firm's ongoing investment strategy in the biotechnology sector.
Versant Vantage II GP, L.P. is a venture capital firm based in San Francisco, California. The firm is part of a network of entities, including Versant Ventures VII GP, L.P. and Versant Vantage II, L.P., all of which are involved in funding and supporting innovative companies in the life sciences space. The firm has been active in recent filings, with the latest report being a Form 3 submission.
The filing reveals that Versant Vantage II GP, L.P. holds no direct securities but is part of a broader ownership structure that includes substantial shares of Series A and Series B Preferred Stock in Lycia Therapeutics, Inc. Specifically, the report indicates that the firm is a ten percent owner of these shares, which are convertible into common stock upon certain conditions. The document states, "Each share of Series A Preferred Stock and Series B Preferred Stock is convertible into Common Stock on a one-for-0.221793422 basis at the option of the holder." This conversion will occur automatically upon the closing of the issuer's initial public offering.
Lycia Therapeutics, Inc. operates in the biological products sector, focusing on innovative treatments without diagnostic substances. The filing indicates that Versant's involvement may strengthen Lycia's position in the market, as venture capital backing often provides essential resources for growth and development.
This update may impact various stakeholders, including investors, competitors, and partners within the biotechnology industry. The significant ownership stakes held by Versant entities suggest a strong belief in Lycia's potential, which could attract further interest from other investors and venture capital firms.
The filing does not specify what happens next regarding these ownership changes, but it underscores the active role of Versant Vantage II GP, L.P. and its affiliates in shaping the future of companies within the life sciences sector.